27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Evotec SE (OTC:EVTCY) has initiated the construction of its J.POD 2 EU biologics manufacturing facility at the company’s Campus Curie in Toulouse, France.
- J.POD 2 EU is Evotec’s second biomanufacturing facility and first commercial biomanufacturing facility in Europe.
- The construction of Evotec’s first J.POD 1 US facility in Redmond, Washington, is on schedule and will be fully operational in H2 2021.
- In addition to J.POD technology, the company is building data-driven scientific capabilities to meet future viral threats, including fast discovery, optimization, and development of novel therapeutic agents.
- The construction of J.POD 2 EU will be supported with up to €50 million from the French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture, and Toulouse Métropole.
- The total investment that Evotec plans to undertake is currently estimated at around €150 million.
- Construction of the J.POD 2 EU facility is expected to begin in H2 2021 and is expected to be fully operational in 2023.
- Price Action: EVTCY shares are up 6% at $40.7 in premarket trading on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!